This company listing is no longer active
Cyclacel Pharmaceuticals Dirección
Dirección controles de criterios 2/4
We currently do not have sufficient information about the CEO.
Información clave
Spiro Rombotis
Chief Executive Officer (CEO)
US$661.0k
Compensación total
| Porcentaje del salario del CEO | 84.7% |
| Permanencia del CEO | 26.6yrs |
| Participación del CEO | 2.2% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 7.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$25m |
| Jun 30 2023 | n/a | n/a | -US$24m |
| Mar 31 2023 | n/a | n/a | -US$23m |
| Dec 31 2022 | US$764k | US$546k | -US$21m |
| Sep 30 2022 | n/a | n/a | -US$19m |
| Jun 30 2022 | n/a | n/a | -US$19m |
| Mar 31 2022 | n/a | n/a | -US$20m |
| Dec 31 2021 | US$1m | US$531k | -US$19m |
| Sep 30 2021 | n/a | n/a | -US$20m |
| Jun 30 2021 | n/a | n/a | -US$18m |
| Mar 31 2021 | n/a | n/a | -US$15m |
| Dec 31 2020 | US$1m | US$531k | -US$12m |
| Sep 30 2020 | n/a | n/a | -US$8m |
| Jun 30 2020 | n/a | n/a | -US$8m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$1m | US$531k | -US$8m |
| Sep 30 2019 | n/a | n/a | -US$8m |
| Jun 30 2019 | n/a | n/a | -US$8m |
| Mar 31 2019 | n/a | n/a | -US$8m |
| Dec 31 2018 | US$753k | US$531k | -US$7m |
| Sep 30 2018 | n/a | n/a | -US$8m |
| Jun 30 2018 | n/a | n/a | -US$14m |
| Mar 31 2018 | n/a | n/a | -US$15m |
| Dec 31 2017 | US$776k | US$531k | -US$15m |
Compensación vs. Mercado: Spiro's total compensation ($USD661.05K) is above average for companies of similar size in the German market ($USD404.23K).
Compensación vs. Ingresos: Spiro's compensation has been consistent with company performance over the past year.
CEO
Spiro Rombotis (64 yo)
26.6yrs
Permanencia
US$661,049
Compensación
Mr. Spiro George Rombotis has been President of Cyclacel Pharmaceuticals Inc. (formerly, Cyclacel Pharmaceuticals, Inc. (formerly known as Cyclacel Group plc)) since August 1997 and has been its Founding C...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 18yrs | US$661.05k | 2.19% € 64.5k | |
| Executive VP of Finance | 18yrs | US$352.62k | 1.19% € 35.0k | |
| Chief Medical Officer & Director | 3.3yrs | US$101.00k | 0.096% € 2.8k | |
| Independent Director | 9.5yrs | US$116.50k | 0.32% € 9.3k | |
| Independent Chairman | 18yrs | US$155.50k | 0.31% € 9.1k | |
| Independent Director | 3.3yrs | US$95.49k | 0.32% € 9.3k | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Vice Chairman | 5.5yrs | US$130.75k | 0.31% € 9.1k | |
| Independent Director | 1.8yrs | US$85.49k | 0.17% € 4.9k |
7.5yrs
Permanencia media
67yo
Promedio de edad
Junta con experiencia: UXI's board of directors are considered experienced (7.5 years average tenure).